Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
IKNA - Ikena Oncology, Inc.
Market Cap 220.71M P/E - EPS this Y 33.10% Ern Qtrly Grth -
Income -66.71M Forward P/E -2.98 EPS next Y 20.20% 50D Avg Chg -17.00%
Sales 1.84M PEG - EPS past 5Y - 200D Avg Chg 19.00%
Dividend N/A Price/Book 1.40 EPS next 5Y - 52W High Chg -32.00%
Recommedations 1.70 Quick Ratio 17.74 Shares Outstanding 48.26M 52W Low Chg 169.00%
Insider Own 6.08% ROA -27.41% Shares Float 13.87M Beta 0.49
Inst Own 78.00% ROE -44.54% Shares Shorted/Prior 272.15K/313.60K Price 5.22
Gross Margin - Profit Margin - Avg. Volume 109,916 Target Price 4.00
Oper. Margin -3,915.18% Earnings Date Nov 7 Volume 105,808 Change -2.06%
Healthcare | Biotechnology | United States
About Ikena Oncology, Inc.

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Ikena Oncology, Inc. News
12/24/24 Ikena Oncology and Inmagene Announce Merger and Fundraising
12/23/24 Sector Update: Health Care Stocks Advance Late Afternoon
12/23/24 Ikena Oncology, Inmagene Sign Merger Deal; Shares Rise
12/23/24 Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
11/13/24 3 US Penny Stocks With Market Caps Over $40M To Consider
11/09/24 Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023)
11/07/24 Ikena Oncology Reports Third Quarter 2024 Financial Results
08/08/24 Ikena Oncology Reports Second Quarter 2024 Financial Results
07/12/24 Best Momentum Stocks to Buy for July 12th
06/01/24 It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year
05/28/24 UPDATE – Ikena Oncology Announces Strategic Update
05/28/24 Ikena Oncology Announces Strategic Update
05/13/24 Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
04/10/24 Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
03/14/24 Ikena Oncology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
03/12/24 Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
08:00 AM Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
02/21/24 Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
02/14/24 Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
01/24/24 Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
ORBIMED ADVISORS LLC Director Director Jun 22 Buy 4.25 252,225 1,071,956 2,098,097 06/24/22
Bonita David P Director Director Jun 22 Buy 4.25 252,225 1,071,956 2,098,097 06/24/22
Zhang Xiaoyan Michelle Chief Scientific Off.. Chief Scientific Officer Jan 10 Option 2.15 1,000 2,150 45,439 01/12/22
Zhang Xiaoyan Michelle Chief Scientific Off.. Chief Scientific Officer Jan 10 Sell 12 1,000 12,000 44,475 01/12/22
Zhang Xiaoyan Michelle Chief Scientific Off.. Chief Scientific Officer Dec 10 Option 2.15 1,000 2,150 45,475 12/14/21
Zhang Xiaoyan Michelle Chief Scientific Off.. Chief Scientific Officer Dec 10 Sell 14.76 1,000 14,760 44,475 12/14/21
FORMELA JEAN FRANCOIS Director Director Mar 30 Buy 16 125,000 2,000,000 874,634 12/14/21
FORMELA JEAN FRANCOIS Director Director Mar 30 Sell 14.56 26,278 382,608 1,241,935 12/14/21
Atlas Venture Fund XI, L.P. 10% Owner 10% Owner Mar 30 Buy 16 125,000 2,000,000 874,634 12/14/21
Atlas Venture Fund XI, L.P. 10% Owner 10% Owner Mar 30 Sell 14.56 26,278 382,608 1,241,935 12/14/21